BiotechTube

Carboplatin + Mirvetuximab Soravtansine + Bevacizumab

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epithelial Ovarian Cancer

Conditions

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant

Trial Timeline

Nov 21, 2025 → Feb 1, 2030

NCT ID
NCT06890338

About Carboplatin + Mirvetuximab Soravtansine + Bevacizumab

Carboplatin + Mirvetuximab Soravtansine + Bevacizumab is a phase 2 stage product being developed by AbbVie for Epithelial Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06890338. Target conditions include Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

What happened to similar drugs?

4 of 13 similar drugs in Epithelial Ovarian Cancer were approved

Approved (4) Terminated (1) Active (9)
🔄Mirvetuximab Soravtansine + Paclitaxel + Topotecan + Pegylated liposomal doxorubicinAbbViePhase 3
🔄AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + TopotecanAstraZenecaPhase 3
🔄Active Comparator: Olaparib tablets + PlaceboAstraZenecaPhase 3
✅Olaparib + BevacizumabAstraZenecaApproved
🔄Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™MerckPhase 3
🔄Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)MerckPhase 3
🔄V501MerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06890338Phase 2Recruiting

Competing Products

20 competing products in Epithelial Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
LY2228820 + Carboplatin + Placebo + GemcitabineEli LillyPhase 1/2
32
gemcitabine + carboplatin + paclitaxelEli LillyPhase 2
35
PemetrexedEli LillyPhase 2
35
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
35
Mirvetuximab Soravtansine + Paclitaxel + Topotecan + Pegylated liposomal doxorubicinAbbViePhase 3
40
Mirvetuximab SoravtansineAbbViePhase 2
42
AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + TopotecanAstraZenecaPhase 3
47
AvelumabAstraZenecaPhase 2
27
Active Comparator: Olaparib tablets + PlaceboAstraZenecaPhase 3
40
Olaparib + carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weeklyAstraZenecaPhase 2
31
Olaparib + BevacizumabAstraZenecaApproved
47
Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™MerckPhase 3
40
PembrolizumabMerckPhase 2
42
MK-1775 and carboplatinMerckPhase 2
35
GardasilMerckPhase 1
29
NG-350A plus PembrolizumabMerckPhase 1
29
Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)MerckPhase 3
40
V501MerckPhase 3
40
9-valent HPV vaccinationMerckPhase 2
42